Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MTSR NASDAQ:PCVX NASDAQ:SDGR NASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMTSRMetsera$52.66-0.2%$40.48$12.30▼$54.47$5.53BN/A1.34 million shs559,842 shsPCVXVaxcyte$43.36-1.3%$34.08$27.66▼$118.54$5.62B1.121.80 million shs1.54 million shsSDGRSchrodinger$20.44-0.8%$19.58$16.60▼$28.47$1.50B1.741.15 million shs1.31 million shsTGTXTG Therapeutics$34.64-1.2%$31.89$22.61▼$46.48$5.50B1.972.38 million shs1.30 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMTSRMetsera+0.50%-0.11%+54.28%+19.14%+5,277,999,900.00%PCVXVaxcyte+2.54%+7.85%+41.74%+17.58%-61.95%SDGRSchrodinger+6.07%-0.53%+11.65%-4.80%+16.77%TGTXTG Therapeutics+2.67%-1.96%+10.39%-10.56%+42.65%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMTSRMetsera$52.66-0.2%$40.48$12.30▼$54.47$5.53BN/A1.34 million shs559,842 shsPCVXVaxcyte$43.36-1.3%$34.08$27.66▼$118.54$5.62B1.121.80 million shs1.54 million shsSDGRSchrodinger$20.44-0.8%$19.58$16.60▼$28.47$1.50B1.741.15 million shs1.31 million shsTGTXTG Therapeutics$34.64-1.2%$31.89$22.61▼$46.48$5.50B1.972.38 million shs1.30 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMTSRMetsera+0.50%-0.11%+54.28%+19.14%+5,277,999,900.00%PCVXVaxcyte+2.54%+7.85%+41.74%+17.58%-61.95%SDGRSchrodinger+6.07%-0.53%+11.65%-4.80%+16.77%TGTXTG Therapeutics+2.67%-1.96%+10.39%-10.56%+42.65%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMTSRMetsera 2.38Hold$55.755.91% UpsidePCVXVaxcyte 2.75Moderate Buy$106.25144.31% UpsideSDGRSchrodinger 2.38Hold$26.2925.01% UpsideTGTXTG Therapeutics 2.67Moderate Buy$49.0042.30% UpsideCurrent Analyst Ratings BreakdownLatest SDGR, PCVX, MTSR, and TGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025PCVXVaxcyteWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/14/2025SDGRSchrodingerWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025MTSRMetseraWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/8/2025SDGRSchrodingerKeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$30.00 ➝ $28.0010/8/2025TGTXTG TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/6/2025TGTXTG TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$60.0010/6/2025TGTXTG TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$60.009/30/2025MTSRMetseraWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$54.009/29/2025SDGRSchrodingerThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$19.009/29/2025SDGRSchrodingerThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold9/27/2025MTSRMetseraWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMTSRMetseraN/AN/AN/AN/A($2.46) per shareN/APCVXVaxcyteN/AN/AN/AN/A$26.52 per shareN/ASDGRSchrodinger$237.92M6.51N/AN/A$5.78 per share3.64TGTXTG Therapeutics$454.07M12.03$0.12 per share284.59$1.43 per share24.08Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMTSRMetsera-$209.13MN/A0.00∞N/AN/AN/AN/AN/APCVXVaxcyte-$463.93M-$4.11N/AN/AN/AN/A-16.85%-15.92%11/4/2025 (Estimated)SDGRSchrodinger-$187.12M-$2.48N/AN/AN/A-76.22%-45.70%-24.81%11/11/2025 (Estimated)TGTXTG Therapeutics$23.38M$0.3792.9234.44N/A13.31%26.05%9.58%11/3/2025 (Estimated)Latest SDGR, PCVX, MTSR, and TGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025SDGRSchrodinger-$0.72N/AN/AN/A$50.51 millionN/A11/4/2025Q3 2025PCVXVaxcyte-$1.23N/AN/AN/AN/AN/A11/3/2025Q3 2025TGTXTG Therapeutics$0.24N/AN/AN/A$152.12 millionN/A8/6/2025Q2 2025PCVXVaxcyte-$1.12-$1.22-$0.10-$1.22N/AN/A8/6/2025Q2 2025SDGRSchrodinger-$0.83-$0.59+$0.24-$0.59$52.03 million$54.76 million8/4/2025Q2 2025TGTXTG Therapeutics$0.32$0.17-$0.15$0.17$147.76 million$141.15 million7/28/2025Q2 2025MTSRMetseraN/A-$0.66N/A-$0.66N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMTSRMetseraN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMTSRMetseraN/A5.265.26PCVXVaxcyteN/A11.1111.11SDGRSchrodingerN/A3.303.30TGTXTG Therapeutics0.893.862.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMTSRMetseraN/APCVXVaxcyte96.78%SDGRSchrodinger79.05%TGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipMTSRMetseraN/APCVXVaxcyte3.10%SDGRSchrodinger21.00%TGTXTG Therapeutics10.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMTSRMetsera81105.06 millionN/AN/APCVXVaxcyte160129.82 million125.80 millionOptionableSDGRSchrodinger79073.61 million58.15 millionOptionableTGTXTG Therapeutics290158.67 million141.78 millionOptionableSDGR, PCVX, MTSR, and TGTX HeadlinesRecent News About These CompaniesTG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of "Moderate Buy" from AnalystsOctober 12, 2025 | marketbeat.comBrokers Offer Predictions for TG Therapeutics Q3 EarningsOctober 10, 2025 | americanbankingnews.comTG Therapeutics (NASDAQ:TGTX) Given Hold (C-) Rating at Weiss RatingsOctober 9, 2025 | marketbeat.comAnalysts Offer Predictions for TG Therapeutics Q3 EarningsOctober 8, 2025 | marketbeat.comHC Wainwright Weighs in on TG Therapeutics FY2029 EarningsOctober 7, 2025 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Raised to "Strong-Buy" at HC WainwrightOctober 7, 2025 | marketbeat.comTG Therapeutics assumed with a Buy at H.C. WainwrightOctober 6, 2025 | msn.comWhat TG Therapeutics (TGTX)'s Six-Year BRIUMVI Safety Data Means For ShareholdersOctober 4, 2025 | uk.finance.yahoo.comInstitutional investors are TG Therapeutics, Inc.'s (NASDAQ:TGTX) biggest bettors and were rewarded after last week's US$176m market cap gainOctober 4, 2025 | finance.yahoo.comTG announces updated data presentations from ULTIMATE I, II Phase 3 trialsSeptember 25, 2025 | msn.comTG Therapeutics, Inc.: New Data for BRIUMVI Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous ...September 24, 2025 | finanznachrichten.deTG Therapeutics Reports Six-Year Data for BRIUMVI® Showing Exceptional Efficacy and Consistent Safety Profile in Multiple Sclerosis TreatmentSeptember 24, 2025 | quiverquant.comQNew Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI TreatmentSeptember 24, 2025 | globenewswire.comWhat is B. Riley's Forecast for TG Therapeutics Q4 Earnings?September 20, 2025 | marketbeat.comStrs Ohio Makes New Investment in TG Therapeutics, Inc. $TGTXSeptember 20, 2025 | marketbeat.comWhat is B. Riley's Estimate for TG Therapeutics Q3 Earnings?September 19, 2025 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 18, 2025 | marketbeat.comB. Riley Forecasts Strong Price Appreciation for TG Therapeutics (NASDAQ:TGTX) StockSeptember 18, 2025 | marketbeat.comTG Therapeutics price target raised to $55 from $53 at B. RileySeptember 17, 2025 | msn.comTG Therapeutics, Inc. $TGTX Position Increased by Voya Investment Management LLCSeptember 17, 2025 | marketbeat.comInsider Selling: TG Therapeutics (NASDAQ:TGTX) Director Sells 20,852 Shares of StockSeptember 13, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSDGR, PCVX, MTSR, and TGTX Company DescriptionsMetsera NASDAQ:MTSR$52.66 -0.12 (-0.23%) As of 03:27 PM EasternMetsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.Vaxcyte NASDAQ:PCVX$43.36 -0.59 (-1.33%) As of 03:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Schrodinger NASDAQ:SDGR$20.43 -0.18 (-0.85%) As of 03:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.TG Therapeutics NASDAQ:TGTX$34.64 -0.41 (-1.16%) As of 03:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift Why Analysts Are Upgrading Ratings After Klarna's IPO 3 Healthcare Companies Insiders Are Buying Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
